Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cellectis SA ( (CLLS) ) has provided an update.
Cellectis S.A. announced its second-quarter 2025 financial results and business updates, highlighting key developments in its clinical programs and strategic partnerships. The company completed end-of-Phase 1 meetings with the FDA and EMA for its UCART22 therapy in relapsed or refractory B-cell acute lymphoblastic leukemia, paving the way for a pivotal Phase 2 trial in the second half of 2025. Additionally, Cellectis is advancing its collaboration with AstraZeneca and expects significant milestones in its ongoing clinical trials, including a Phase 1 readout for UCART20x22 in late 2025. Financially, Cellectis reported $230 million in cash and equivalents as of June 30, 2025, providing a runway into the second half of 2027.
The most recent analyst rating on (CLLS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s stock score is primarily driven by its strong technical performance, reflecting current market optimism and momentum. Despite this, the company’s financial performance is hampered by profitability challenges, and the valuation presents significant risks due to ongoing losses. The absence of earnings call insights and corporate events means these factors did not influence the score.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company that utilizes its pioneering gene editing platform to develop cell and gene therapies aimed at treating life-threatening diseases. The company focuses on creating solutions for patients with unmet medical needs, particularly in the areas of oncology and genetic disorders.
Average Trading Volume: 134,016
Technical Sentiment Signal: Buy
Current Market Cap: $207.8M
See more data about CLLS stock on TipRanks’ Stock Analysis page.